NCT07904845
A Study of BON-C1393 in Adults With Advanced Solid Tumors
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 9 words
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Phase 1a: Number of Participants with Dose-Limiting Toxicities (DLTs)
Timeframe: Approximately 1 month
Phase 1a: Number of Participants with Treatment-emergent Adverse Events (TEAEs), Treatment-related Adverse Events (TRAEs), and Serious Adverse Events (SAEs)
Timeframe: Up to approximately 9 months
Phase 1b: Overall Response Rate (ORR) Assessed by the Investigator
Timeframe: Up to approximately 12 months
Secondary (13)
Phase 1a: Overall Response Rate (ORR) Assessed by the Investigator
Phase 1a: Duration of Response (DOR) Assessed by the Investigator
Phase 1b: Duration of Response (DOR) Assessed by the Investigator
Phase 1a: Disease Control Rate (DCR) Assessed by the Investigator
Phase 1b: Disease Control Rate (DCR) at 12 Weeks Assessed by the Investigator
Show 8 moreShow less
Phase 1b: Disease Control Rate (DCR) at 24 Weeks Assessed by the Investigator
Phase 1b: Progression-free Survival (PFS) Assessed by the Investigator
Area Under the Concentration Time Curve (AUC) of BON-C1393
Maximum Observed Plasma Concentration (Cmax) of BON-C1393
Time to Maximum Plasma Concentration (Tmax) of BON-C1393
Terminal Half-Life (t1/2) of BON-C1393
Plasma Concentrations of BON-C1393
Phase 1b: Number of Participants with Adverse Events
Arms and interventions
Phase 1a Part A: Monotherapy Dose EscalationExperimental
Sequential cohorts of increasing dose levels of BON-C1393 will be evaluated.
Phase 1a Part B: Monotherapy Dose ExplorationExperimental
Participants with select advanced solid tumors will receive BON-C1393 at 2 - 3 selected dose levels that have been determined to be safe in Part A.
Phase 1b Part C: Monotherapy Dose ExpansionExperimental
Participants with select advanced solid tumors will receive BON-C1393 as monotherapy at the recommended doses for expansion (RDFEs) identified in Phase 1a.
Phase 1b Part D: Dose Expansion Combination TherapyExperimental
Participants with select advanced solid tumors will receive BON-C1393 in combination with bevacizumab and capecitabine.
Drugs: BON-C1393, Bevacizumab, Capecitabine